Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.

  title={Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.},
  author={Heyan Li and Songwen Zhou and Xuefei Li and Daoyuan Wang and Yong-sheng Wang and Caicun Zhou and Gerald Schmid-Bindert},
  journal={Cancer biotherapy & radiopharmaceuticals},
  volume={28 2},
Recent evidence indicates that both the phosphatidylinositol 3-kinase (PI3K)/AKT and the MEK/ERK pathways are strictly regulated by epidermal growth factor receptor in non-small cell lung cancer (NSCLC) that responds to Gefitinib. Gefitinib resistance is partly owing to the activation of two major downstream signaling pathways PI3K/AKT or MEK/ERK. In this study, we found that in Gefitinib-sensitive cell lines, Gefitinib could induce tumor cell apoptosis via upregulation of a proapoptotic… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 12 extracted citations

Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2015

c-Met and miRs in Cancer

Biomedicines • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…